Antag Therapeutics is based on years of collaborative research from the University of Copenhagen with the focus on novel treatments for dietary-related metabolic diseases. The research teams of professor Mette Rosenkilde and professor Jens Juul Holst have discovered a naturally occurring peptide that is being investigated in several human studies.
Focus area
The global prevalence of dietary-related metabolic diseases (obesity and type 2 diabetes mellitus) is enormous and continues to increase due to excessive caloric intake, inactive lifestyle, and the lack of effective treatment.
Obesity
According to WHO, more than 650 million people worldwide suffer from obesity, and the number increases every year. Obesity leads to comorbidities such as type 2 diabetes, fatty liver disease, stroke, coronary artery disease, cancer and many more. Unfortunately, both dieting, exercise and current pharmacological intervention rarely meet the expectations of physicians and patients.
Type 2 diabetes
Diabetes is a progressive metabolic disease characterized by distorted insulin and/or glucagon physiology leading to the development of hyperglycemia. The complications of diabetes are serious and include damage to multiple organ systems particularly kidneys, eyes, nerves, and blood vessels. Currently, available treatments have many drawbacks, including tolerability issues, weight gain, and loss of efficacy over time.
Orphan disease
We are exploring our technology’s application as a treatment for an orphan disease to improve the lives of these patients.
Our drugs are based on a novel, effective, and naturally occurring antagonist that modulates fat metabolism and dysregulation of glycemia in diabetic patients.
Team
Prof. Jens Juul Holst
MD, DMSC, Co-founder
Discoverer of GLP-1, with over 1200 publications. The most cited living physiologist between 1996-2006.
Philip Just Larsen
MD, PhD
CSO of Grunenthal Group and former CSO of Sanofi (Germany) and former CSO of Diabetes research at Eli Lilly.
Anker Lundemose
MD, PhD, DMSc
CEO of Mission Therapeutics with a track record in biotech M&A, BD&L and VC investment.
.
Kirsten Drejer
M.Sc., PhD
Co-founder and former CEO of Symphogen with a long history of leadership positions at Novo Nordisk.
Emmanuelle Coutanceau
PhD, Partner at Novo Holdings
Partner at Novo Holdings with over 10 years of experience in VC investment.
.
Alexander Hovard Sparre-Ulrich
M.Sc., PhD, Co-founder, CEO
Award winning innovator that has led all commercialisation and development aspects since 2014.
.
Prof. Mette Marie Rosenkilde
MD, PhD, Co-founder, Acting CSO
Has a proven track record of translating innovative discoveries into spin-out companies.
Mikael Thomsen
M.Sc., PhD, Acting CDO
Extensive biotech experience in managing the activities necessary for taking a compound from late discovery to Phase II/cPoC.
.
Jakob Dynnes Hansen
M.Sc., MBA, Acting CFO
Has more than 25 years of combined experience from biotech and financing.
.
.
Ian Laquian
M.Sc., MBA, Acting CBO
EIR at Novo Seeds with extensive pharma & biotech experience.
.
.
.